SLC33A1
The encoded protein is required for the formation of O-acetylated (Ac) gangliosides. It is predicted to contain 6 to 10 transmembrane domains, and a leucine zipper motif in transmembrane domain III. Studies indicate that the protein is localized to the cytoplasm. [provided by RefSeq]
Full Name
solute carrier family 33 (acetyl-CoA transporter), member 1
Function
Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides (PubMed:9096318).
Negatively regulates BMP signaling (PubMed:25402622).
Negatively regulates BMP signaling (PubMed:25402622).
Biological Process
Transmembrane transportTAS:Reactome
Cellular Location
Endoplasmic reticulum membrane
Involvement in disease
Spastic paraplegia 42, autosomal dominant (SPG42):
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
Congenital cataracts, hearing loss, and neurodegeneration (CCHLND):
An autosomal recessive disorder characterized by congenital cataracts, severe psychomotor retardation, and hearing loss associated with decreased serum ceruloplasmin and copper. Brain MRI shows cerebral and cerebellar atrophy and hypomyelination.
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
Congenital cataracts, hearing loss, and neurodegeneration (CCHLND):
An autosomal recessive disorder characterized by congenital cataracts, severe psychomotor retardation, and hearing loss associated with decreased serum ceruloplasmin and copper. Brain MRI shows cerebral and cerebellar atrophy and hypomyelination.
View more
Anti-SLC33A1 antibodies
+ Filters
Loading...
Target: SLC33A1
Host: Mouse
Antibody Isotype: IgG2a, κ
Specificity: Human, Rat
Clone: 3A4
Application*: WB, E
Target: SLC33A1
Host: Mouse
Antibody Isotype: IgG
Specificity: Human, Rat
Clone: CBXS-3003
Application*: E, WB
More Infomation
Hot products 
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Armenian hamster Anti-CD40 Recombinant Antibody (HM40-3) (CBMAB-C10365-LY)
-
Mouse Anti-NSUN6 Recombinant Antibody (D-5) (CBMAB-N3674-WJ)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-ADRB2 Recombinant Antibody (V2-180026) (CBMAB-A1420-YC)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Rat Anti-ADGRE4 Recombinant Antibody (V2-160163) (CBMAB-F0011-CQ)
-
Mouse Anti-CD1C Recombinant Antibody (L161) (CBMAB-C2173-CQ)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Mouse Anti-EGR1 Recombinant Antibody (CBWJZ-100) (CBMAB-Z0289-WJ)
-
Rabbit Anti-ATF4 Recombinant Antibody (D4B8) (CBMAB-A3872-YC)
-
Mouse Anti-DISP2 Monoclonal Antibody (F66A4B1) (CBMAB-1112CQ)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Mouse Anti-AMACR Recombinant Antibody (CB34A) (CBMAB-CA034LY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




